Edwards Lifesciences Corporation
HealthcareNYSE:EW · New York Stock Exchange
-$1.03 today
Vol 2.19M · Avg 5.38M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.4%
avg 23.1%
ROIC
11.4%
avg 16.2%
ROA
7.8%
avg 15.2%
Analysis
ROIC is currently the strongest return metric at 11.4% versus its period average of 16.2%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bernard J. Zovighian | Chief Executive Officer & Director | $3.79M | — | 58 | $41,030.91 | <0.01% |
Scott Ullem | Corporate Vice President & Chief Financial Officer | $1.85M | — | 59 | $57,744.00 | 0.01% |
Theodora Mistras | Corporate Vice President & Chief Financial Officer | $1.85M | — | 44 | $0.00 | <0.01% |
Annette Maria Bruls | Corporate Vice President of EMEA, Canada, & Latin America | $1.63M | — | 55 | $20,737.00 | <0.01% |
Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development | $1.60M | — | 64 | $98,611.00 | 0.02% |
Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | $1.56M | — | 47 | $44,324.00 | <0.01% |
Todd Brinton FACC | Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer | — | — | — | — | — |
Andrew Dahl | Principal Accounting Officer, Senior Vice President & Corporate Controller | — | — | 48 | $15,334.09 | <0.01% |
Dirksen J. Lehman | Corporate Vice President of Public Affairs | — | — | — | $41,030.91 | <0.01% |
Gary I. Sorsher | Senior Vice President of Quality & Regulatory Compliance | — | — | 61 | — | — |
Joseph Nuzzolese | Corporate Vice President of Global Operations & Quality | — | — | — | — | — |
Mark D. Peterson | Corporate Vice President & General Counsel | — | — | 63 | — | — |
Snehashish Sarkar | Senior VP and Chief Information & Digital Officer | — | — | 51 | — | — |
Wayne T. Markowitz | GM & Senior VP of Surgical Structural Heart | — | — | 53 | $21,679.87 | <0.01% |
Christine Z. McCauley | Corporate Vice President of Human Resources | — | — | 61 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
44
$24.95M
Net Sentiment
$24.95M
Net selling
Most Active
BOBO DONALD E JR
12 transactions
1–10 of 44
Analysis
Insiders reported 0 buys worth $0.00 and 44 sells worth $24.95M over the last 12 months. That adds up to net selling of $24.95M. BOBO DONALD E JR was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +22.3% | +12.8% (15yr)5 analysts |
| Revenue | N/A | N/A | +9.5% | +9.5% (15yr)11 analysts |
| Net Income | N/A | N/A | +19.1% | +11.9% (15yr)11 analysts |
| EBIT | N/A | N/A | +13.2% | +11.2% (15yr)11 analysts |
Analysis
Recent growth has been strongest in EPS at +22.3% over three years. Forward estimates point to EPS at +12.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
argenx SE
NASDAQ:ARGX
$55.60B
Becton, Dickinson and Company
NYSE:BDX
$52.82B
Cardinal Health, Inc.
NYSE:CAH
$52.35B
Haleon plc
NYSE:HLN
$40.28B
Agilent Technologies, Inc.
NYSE:A
$36.52B
Alcon Inc.
NYSE:ALC
$32.50B
DexCom, Inc.
NASDAQ:DXCM
$28.77B
Veeva Systems Inc.
NYSE:VEEV
$25.79B
STERIS plc
NYSE:STE
$20.29B
Bruker Corporation
NASDAQ:BRKR
$8.16B
Who manages EW?
Edwards Lifesciences Corporation (EW) lists 15 active executives. The top listed executive is Todd Brinton FACC, Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer.
Are EW insiders buying or selling?
Recent insider activity shows net buying of $743,451.23.
Explore More
Continue the stock analysis
Jump to another research area for this company.